

25 Jul 2021 |

# Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: J&J's outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen's views on Aduhelm pricing; competition in the "dustat" sector; and dealing with endemic COVID-19.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 23 July 2021, including: [Johnson & Johnson's](#) outlook for coronavirus vaccines; Cosentyx comes in strong for [Novartis AG](#); [Biogen, Inc.](#)'s views on Aduhelm pricing; competition in the "dustat" sector; and dealing with endemic COVID-19..

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[J&J's COVID-19 Vaccine On Track To Generate \\$2.5bn This Year](#)" - Scrip, 21 Jul, 2021.)

(Also see "[Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing](#)" - Scrip, 21 Jul, 2021.)

(Also see "[Biogen: Aduhelm Price Is Part Of Alzheimer's 'Evolution'](#)" - Scrip, 20 Jul, 2021.)

(Also see "[GSK Looks To Capitalize On AstraZeneca's Anemia Drug Knock-Back](#)" - Scrip, 16 Jul, 2021.)

(Also see "[\*Global Herd Immunity Against COVID-19 Unlikely, Says Ebola Vaccine Developer\*](#)" - Scrip, 20 Jul, 2021.)

[Click here to explore this interactive content online](#) ✎